LABFF.US Laboratorios Farmaceuticos Rovi S.A
- Market cap
- USD 3.44B
- P/E
- 15.9x
- P/B
- 4.40x
- ROE
- 27.2%
- Dividend yield
- 1.63%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LABFF.US undervalued?
Graham numberLABFF.US trades 76.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Laboratorios Farmaceuticos Rovi S.A fundamental analysis
No fundamental analysis for Laboratorios Farmaceuticos Rovi S.A yet.
Laboratorios Farmaceuticos Rovi S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Laboratorios Farmaceuticos Rovi S.A
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, …
Full company profileLaboratorios Farmaceuticos Rovi S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Laboratorios Farmaceuticos Rovi S.A annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 265M | 276M | 303M | 381M | 420M | 649M | 818M | 830M | 764M | 743M | 807M |
| Gross Profit | 150M | 162M | 171M | 211M | 237M | 380M | 512M | 483M | 468M | 451M | 532M |
| Operating Income | 28.3M | 19.0M | 17.5M | 42.8M | 74.7M | 181M | 256M | 220M | 180M | 173M | 162M |
| EBITDA | 33.8M | 26.7M | 27.9M | 60.2M | 94.5M | 202M | 277M | 244M | 207M | 216M | 287M |
| Net Income | 26.1M | 17.2M | 17.9M | 39.3M | 61.1M | 153M | 200M | 170M | 137M | 140M | 215M |
| EPS | 0.53 | 0.35 | 0.35 | 0.71 | 1.10 | 2.76 | 3.73 | 3.20 | 2.67 | 2.74 | 4.20 |
| Balance Sheet | |||||||||||
| Total Assets | 288M | 298M | 403M | 511M | 574M | 733M | 879M | 800M | 832M | 955M | 1.15B |
| Total Liabilities | 104M | 107M | 115M | 189M | 201M | 262M | 357M | 256M | 250M | 277M | 343M |
| Shareholders' Equity | 183M | 192M | 287M | 322M | 374M | 471M | 520M | 539M | 572M | 664M | 791M |
| Cash & Short-term Investments | 41.4M | 40.7M | 95.5M | 67.4M | 53.2M | 99.0M | 125M | 25.4M | 27.4M | 97.9M | 71.9M |
| Total Debt | 33.8M | 43.2M | 34.2M | 84.7M | 73.5M | 73.1M | 72.1M | 65.4M | 114M | 122M | 102M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 45.5M | 18.0M | 8.53M | -9.04M | 46.9M | 149M | 238M | 113M | 138M | 185M | 145M |
| Capital Expenditure | 18.1M | 19.9M | 26.5M | 40.5M | 39.7M | 40.9M | 51.4M | 55.2M | 62.2M | 65.2M | 65.1M |
| Free Cash Flow | 27.5M | -1.91M | -17.9M | -49.6M | 7.18M | 109M | 186M | 58.1M | 76.1M | 120M | 80.1M |
| Ratios | |||||||||||
| ROE | 14.2% | 9.0% | 6.2% | 12.2% | 16.3% | 32.5% | 38.4% | 31.6% | 23.9% | 21.1% | 27.2% |
| ROA | 9.1% | 5.8% | 4.4% | 7.7% | 10.6% | 20.9% | 22.7% | 21.3% | 16.5% | 14.7% | 18.6% |
| Net Profit Margin | 9.8% | 6.3% | 5.9% | 10.3% | 14.5% | 23.6% | 24.4% | 20.5% | 17.9% | 18.9% | 26.7% |
| Debt to Equity | 0.18x | 0.23x | 0.12x | 0.26x | 0.20x | 0.16x | 0.14x | 0.12x | 0.20x | 0.18x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Laboratorios Farmaceuticos Rovi S.A dividends
- Dividend yield
- 1.63%
- Forward dividend
- 1.10 USD
- Payout ratio
- 34.1%
- Ex-dividend date
- Jul 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 47.8M | 0.93 | 34.1% |
| 2024 | EUR 56.5M | 1.10 | 41.2% |
| 2023 | EUR 69.0M | 1.30 | 40.5% |
| 2022 | EUR 51.0M | 0.95 | 25.5% |
| 2021 | USD 21.1M | 0.38 | 13.8% |
| 2020 | USD 9.70M | 0.18 | 15.9% |
| 2019 | USD 4.42M | 0.08 | 11.3% |
| 2018 | USD 5.95M | 0.12 | 33.3% |
| 2017 | USD 9.03M | 0.18 | 52.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Laboratorios Farmaceuticos Rovi S.A
- Insiders 68.20%
- Institutions 16.61%
- Public & others 15.19%
- Shares outstanding 51.1M
- Free float 16.2M
Laboratorios Farmaceuticos Rovi S.A company profile
- Company name
- Laboratorios Farmaceuticos Rovi S.A
- Ticker
- LABFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,950
- Fiscal year end
- December
- Address
- Calle José Isbert, 2, Pozuelo de Alarcón, Spain, 28223
- Phone
- 34 91 021 30 00
- Website
- rovi.es
About Laboratorios Farmaceuticos Rovi S.A
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Laboratorios Farmaceuticos Rovi S.A management
10- Mr. Juan Lopez-Belmonte EncinaChairman & CEO
- Mr. Ivan Jorge Lopez-Belmonte EncinaSecond Deputy Chairman and Chief Commercial & Development Officer
- Mr. Javier Lopez-Belmonte EncinaFirst Deputy Chairman, GM of Industrial Operations & CFO
- Ms. María Álvarez SolasChief Operating Officer
- Ms. Marta Campos MartínezHead of Investor Relations
- Ms. Mercedes Benítez del Castillo SánchezChief Legal Officer
- Ms. Alicia Hurtado MoralesChief Compliance Officer
- Ms. Rosario Perucha PérezMarketing Director
- Mr. Francisco Javier Angulo GarcíaHuman Resources Manager
- Mr. Miguel Ángel Ortega SánchezChief Industrial Officer